sponsored
PatientsVille.com Logo

PatientsVille

Methylprednisolone 4mg tab Medical Research Studies

Up-to-date List of Methylprednisolone 4mg tab Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Methylprednisolone 4mg tab Medical Research Studies

Rank Status Study
1 Recruiting Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (MK-3641-006)
Condition: Rhinitis, Allergic, Seasonal
Interventions: Biological: MK-3641 12 Amb a 1-U (short ragweed extract);   Biological: MK-7243 2800 BAU (Timothy grass extract);   Drug: Rescue Medication
Outcome Measures: Percentage of Participants Who Experience at Least One Event of Local Swelling;   Percentage of Participants Who Experience at Least One Event of Local Application Site Reaction;   Percentage of Participants Who Discontinue From the Study Due to an Adverse Event (AE);   Percentage of Participants Who Experience at Least One Local Application Site Reaction that Requires Symptomatic Treatment
2 Recruiting Vaccine Therapy in Curative Resected Prostate Cancer Patients
Condition: Prostate Cancer
Intervention: Biological: Dendritic cell vaccine
Outcome Measures: Time to treatment failure defined by two different measurement of PSA levels >0.5 µg/L with minimum of 4 weeks interval in patients receiving treatment;   Safety and toxicity of vaccination. Evaluation of immunological response.
3 Recruiting Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia
Conditions: Asthma;   Eosinophilia;   Helminthiasis;   Hypersensitivity;   Parasitic Disease
Intervention:
Outcome Measure:
4 Recruiting Use of Compression Glove to Prevent Complications After Distal Radius Fractures: a Randomized Controlled Trial
Conditions: Post-traumatic Carpal Tunnel Syndrome;   Complex Regional Pain Syndrome;   Edema
Intervention: Device: Compression glove
Outcome Measures: Incidence of Post-traumatic Carpal Tunnel Syndrome (CTS);   Incidence of Complex Regional Pain Syndrome;   Edema;   Grip strength;   Disabilities of the Arm, Shoulder, & Hand questionnaire;   Pain;   Time-to-recovery
5 Recruiting Chalazia Treatment Study
Condition: Chalazion
Interventions: Drug: 5-fluorouracil Injection;   Drug: Triamcinolone Acetonide;   Procedure: Incision and Curettage;   Drug: Triamcinolone Acetonide/5-fluorouracil mixture
Outcome Measure: Size of chalazion
6 Unknown  Open Versus Percutaneous Insertion of CAPD Catheters
Condition: Renal Failure
Interventions: Procedure: Percutaneous Insertion catheter;   Procedure: Open insertion Catheter
Outcome Measures: Catheter survival;   Peri operative complications (bleeding, bowel injury);   Mechanical Complication (drainage failure, displacement, fluid leak);   Infective complications (exit site, tunnel, peritonitis);   Operative time;   Technical Success of placement;   Length of admission;   Patient reported pain post procedure;   Quality of life assessment by questionnaire;   Estimated cost of care episode
7 Recruiting Safety Study of Long-Acting Local Anesthetic
Condition: Safety of Neosaxitoxin in Healthy Adult Male Volunteers
Interventions: Drug: Neosaxitoxin (NeoSTX) in saline;   Drug: NeoSTX with 0.2% bupivacaine;   Other: Placebo
Outcome Measures: Presence or absence of Adverse Events as a function of NeoSTX dose;   Pharmacokinetic parameters characterizing uptake and distribution of NeoSTX (content in serum and urine samples);   Cutaneous sensory blockade (numbness);   Local skin reactions (edema, paresthesias and urticaria)
8 Unknown  High Volume Saline Injections for Achilles Tendinopathy
Condition: Achilles Tendinopathy
Interventions: Procedure: Ultrasound guided injection of steroid and local anaesthetic;   Procedure: High volume saline injection;   Behavioral: exercise programme
Outcome Measures: 100mm Visual Analogue 100mm Visual Analogue Pain Score;   Foot and Ankle Outcome Score;   EQ5D-3L;   Diameter of symptomatic achilles tendon by ultrasound scan;   Neovascularisation grading;   all outcome measures
9 Recruiting A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall
Condition: Soft Tissue Sarcoma
Interventions: Radiation: proton radiation;   Procedure: surgery (wide local excision; limb preservation surgery)
Outcome Measures: Late radiation toxicities (>grade 2 lymphedema, subcutaneous fibrosis, and joint stiffness);   Grade 3-5 adverse events (CTCAE, v4.0);   Composite patterns of failure, including local failure (in-field, marginal, out-of-field), regional failure, distant failure, and death without disease progression;   Composite measures of local failure, including local-regional failure, distant failure, distant-disease-free survival, disease-free survival, overall survival rates, and second primary tumor;   Wound complication rates;   Degree of late radiation morbidity at 2 years with quality of life assessment (FACT-G)
10 Unknown  Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema
Condition: Chronic Venous Insufficiency (CVI)
Intervention: Device: V0322 BC
Outcome Measures: Volume reduction of the target leg presenting the most important initial volume (by Volumetry using water displacement);   Functional symptoms by VAS (pain, heaviness) at each visit by the patient.;   Quality of life. SQOR-V and ABC-V (FARDEAU) score;   Body weight variation;   Suprafacial Thickness Measured Duplex measurement;   Assessment of local tolerance (examination of the skin) and safety (general clinical examination and reported adverse events)
11 Unknown  Olive Oil With Omega 3 to Treat Stasis Dermatitis
Condition: Dermatitis
Intervention: Drug: olive oil and omega 3 in a combined cream
Outcome Measure: improvement in subjective and objective skin changes of patient: pain, edema, redness, size of involement,
12 Not yet recruiting Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Condition: Efficacy and Safety of Ranibizumab (Lucentis)
Intervention: Drug: Lucentis Intravitreal injections
Outcome Measures: Mean Change from baseline in Best Correct Visual Acuity (BCVA);   National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) composite score
13 Recruiting REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study
Condition: Abdominal Surgery
Interventions: Other: Liberal fluid therapy;   Other: Restrictive fluid therapy
Outcome Measures: Disability-free survival;   Death;   Sepsis;   Surgical site infection;   Pneumonia;   Acute kidney injury;   Pulmonary oedema;   Total ICU stay and mechanical ventilation time;   Hospital stay;   Quality of recovery
14 Recruiting Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina
Conditions: Macular Edema;   Central Serous Chorioretinopathy;   Retinal Vein Occlusion;   Age-related Macular Degeneration;   Retinal Neovascularization
Intervention: Device: Selective retinal pigment epithelium laser therapy using SRT Vario Laser
Outcome Measures: Visual Acuity according to ETDRS protocol;   Retinal thickness measured by optical coherence tomography;   Leakage of fluorescein in fluorescein angiography;   Area of absent fundus autofluorescence
15 Recruiting Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine in Healthy Female Children
Condition: Infections, Papillomavirus
Interventions: Biological: Cervarix;   Biological: MMR;   Biological: DTPa
Outcome Measures: The occurrence of solicited local adverse events (AEs) in Groups HPV_2D and MMR_DTPa.;   The occurrence of solicited general AEs in Groups HPV_2D and MMR_DTPa.;   The occurrence of unsolicited AEs in Groups HPV_2D and MMR_DTPa.;   Occurrence of unsolicited AEs in Groups HPV_2D and MMR_DTPa.;   The occurrence of clinically relevant abnormalities in biochemical and haematological parameters in Groups HPV_2D and MMR_DTPa.;   Occurrence of clinically relevant abnormalities in biochemical and haematological parameters in Groups HPV_2D and MMR_DTPa.;   The occurrence of serious adverse events (SAEs) in Groups HPV_2D and MMR_DTPa.;   The occurrence of AEs and SAEs leading to withdrawal in Groups HPV_2D and MMR_DTPa.;   The occurrence of potential immune-mediated diseases (pIMDs) in Groups HPV_2D and MMR_DTPa.;   The occurrence of medically significant conditions (MSCs) in Groups HPV_2D and MMR_DTPa.;   Anti-HPV-16/18 seroconversion rates assessed by Enzyme-Linked Immunosorbent Assay (ELISA) in Groups HPV_2D and HPV_3D;   Anti-HPV-16/18 antibody titres assessed by ELISA in Groups HPV_2D and HPV_3D;   Anti-HPV-16/18 seroconversion rates assessed by ELISA in Group MMR_DTPa;   Anti-HPV-16/18 antibody titres assessed by ELISA in Group MMR_DTPa;   Anti-HPV-16/18 seroconversion rates assessed by ELISA in Groups HPV_2D, HPV_2D CO and HPV_3D.;   Anti-HPV-16/18 antibody titres assessed by ELISA in Groups HPV_2D, HPV_2D CO and HPV_3D.;   Anti-HPV-16/18 seroconversion rates assessed by Pseudovirion-Based Neutralization Assay (PBNA) in a sub-cohort in Group MMR_DTPa;   Anti-HPV-16/18 antibody titres assessed by PBNA in a sub-cohort in Group MMR_DTPa;   Anti-HPV-16/18 seroconversion rates assessed by PBNA in a sub-cohort in Groups HPV_2D, HPV_2D CO and HPV_3D.;   Anti-HPV-16/18 antibody titres assessed by PBNA in a sub-cohort in Groups HPV_2D, HPV_2D CO and HPV_3D.;   Anti-measles, mumps and rubella seropositivity rates in Groups HPV_2D, MMR_DTPa and HPV_2D CO.;   Anti-measles, mumps and rubella antibody titres in Groups HPV_2D, MMR_DTPa and HPV_2D CO.;   Vaccine response rates to filamentous haemagglutinin (FHA), pertactin (PRN) and pertussis toxoid (PT) antigens in Groups HPV_2D, MMR_DTPa and HPV_2D CO.;   Seroprotection rates to diphtheria (D) and tetanus (T) antigens in Groups HPV_2D, MMR_DTPa and HPV_2D CO.;   The occurrence of solicited local AEs in all groups.;   The occurrence of solicited general AEs in all groups.;   The occurrence of solicited fever, measles/rubella-like rash, parotid gland swelling and signs of meningism, including febrile convulsion, in Groups MMR_DTPa and HPV_2D CO.;   The occurrence of unsolicited AEs in Groups HPV_2D, MMR_DTPa and HPV_2D CO.;   The occurrence of unsolicited symptoms in Groups HPV_3D, HPV_2D, MMR_DTPa and HPV_2D CO.;   The occurrence of clinically relevant abnormalities in biochemical and haematological parameters in Groups HPV_2D, MMR_DTPa and HPV_2D CO.;   Occurrence of clinically relevant abnormalities in biochemical and haematological parameters in Groups HPV_2D, MMR_DTPa and HPV_2D CO.;   The occurrence of pIMDs in all groups.;   The occurrence of MSCs in all groups.;   The occurrence of SAEs in all groups.;   The occurrence of SAEs related to the investigational products, to study participation, to GSK concomitant products or any fatal SAE in all groups.;   The occurrence of AEs/SAEs leading to withdrawal in all groups.;   The occurrence of pregnancy and pregnancy outcomes in Group HPV_3D.;   Number of subjects reporting the intake of concomitant medication in Groups HPV_2D, MMR_DTPa and HPV_2D CO.;   Number of subjects reporting the intake of concomitant medication in all groups.;   The percentage of subjects completing the vaccination schedule in all groups.
16 Recruiting Preconditioning Shields Against Vascular Events in Surgery
Conditions: Abdominal Aortic Aneurysm;   Carotid Atherosclerosis;   Critical Lower Limb Ischaemia
Intervention: Procedure: Remote ischaemic preconditioning
Outcome Measures: Serum troponin levels;   Composite Major Adverse Clinical Events;   Duration of post-operative hospital stay;   Duration of intensive care unit stay;   Unplanned critical care unit admission;   Acute kidney injury score in first three peri-operative days;   Post-operative complications;   Mortality;   Cardiac or cerebral event;   Acute upper limb ischaemia;   Acute upper limb deep vein thrombosis;   Serial troponin I results
17 Recruiting Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
Conditions: Wet Age Related Macular Degeneration;   Diabetic Macular Edema;   Retinal Vein Occlusion
Intervention: Other: Ranibizumab
Outcome Measures: Incidence rate, relationship and severity of treatment emergent ocular and non-ocular adverse events;   Mean visual acuity at quarterly intervals for the primary treated eye set;   Overall number of ranibizumab injections, number of visits, time interval between injections, duration of treatment, number of re-treatment, and reasons for treatment termination;   Change from baseline in National Eye Institute Visual Function Questionnaire 25 composite and sub-scale scores
18 Not yet recruiting Electrical Impedance Imaging of Patients on Mechanical Ventilation
Conditions: Pneumothorax;   Pulmonary Contusion;   Pleural Effusion;   Pulmonary Edema;   Atelectasis;   Hyperinflation;   Emphysema;   Acute Respiratory Distress Syndrome
Interventions: Device: Mechanical Ventilation;   Device: CT Scan
Outcome Measures: Sensitivity and specificity for diagnosing lung pathology;   Regional correlation with CT scan
19 Recruiting Preconditioning Shields Against Vascular Events in Surgery
Conditions: Abdominal Aortic Aneurysm;   Carotid Atherosclerosis;   Critical Lower Limb Ischaemia
Intervention: Procedure: Remote preconditioning
Outcome Measures: Major Adverse Clinical Events;   Duration of post-operative hospital stay;   Duration of intensive care unit stay;   Unplanned critical care unit admission;   Acute kidney injury score in first three peri-operative days;   Peri-operative myocardial injury
20 Recruiting The Effect of Peritonsillar Infiltration of Ketamine and Dexamethasone for Postoperative Pain Relief in Children Following Adenotonsillectomy
Condition: Tonsillectomy
Interventions: Drug: saline;   Drug: Ketamine;   Drug: Dexamethasone;   Drug: ketamine-dexamethasone
Outcome Measures: pain will be assessed by [observational pain scores (OPS)];   pain will be assessed by [observational pain scores (OPS)];   time to first demand of analgesia;   postoperative analgesic consumption;   nausea, vomiting will be assessed by questioning their parents.;   bleeding will be assessed by questioning their parents;   family satisfaction will be assessed by questioning their parents.

These studies may lead to new treatments and are adding insight into Methylprednisolone 4mg tab etiology and treatment.

A major focus of Methylprednisolone 4mg tab research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Methylprednisolone 4mg tab